Venugopala Katharigatta N, Uppar Vijayakumar, Chandrashekharappa Sandeep, Abdallah Hassan H, Pillay Melendhran, Deb Pran Kishore, Morsy Mohamed A, Aldhubiab Bandar E, Attimarad Mahesh, Nair Anroop B, Sreeharsha Nagaraja, Tratrat Christophe, Yousef Jaber Abdulmuttaleb, Venugopala Rashmi, Mailavaram Raghu Prasad, Al-Jaidi Bilal A, Kandeel Mahmoud, Haroun Michelyne, Padmashali Basavaraj
Department of Pharmaceutical Sciences, College of Clinical Pharmacy, King Faisal University, Al-Ahsa 31982, Saudi Arabia.
Department of Biotechnology and Food Technology, Durban University of Technology, Durban 4001, South Africa.
Antibiotics (Basel). 2020 May 7;9(5):233. doi: 10.3390/antibiotics9050233.
A series of ethyl 1-(substituted benzoyl)-5-methylpyrrolo[1,2-]quinoline-3-carboxylates - and dimethyl 1-(substituted benzoyl)-5-methylpyrrolo[1,2-]quinoline-2,3-dicarboxylates - have been synthesized and evaluated for their anti-tubercular (TB) activities against H37Rv (American Type Culture Collection (ATCC) strain 25177) and multidrug-resistant (MDR) strains of by resazurin microplate assay (REMA). Molecular target identification for these compounds was also carried out by a computational approach. All test compounds exhibited anti-tuberculosis (TB) activity in the range of 8-128 µg/mL against H37Rv. The test compound dimethyl-1-(4-fluorobenzoyl)-5-methylpyrrolo[1,2-]quinoline-2,3-dicarboxylate emerged as the most promising anti-TB agent against H37Rv and multidrug-resistant strains of at 8 and 16 µg/mL, respectively. In silico evaluation of pharmacokinetic properties indicated overall drug-likeness for most of the compounds. Docking studies were also carried out to investigate the binding affinities as well as interactions of these compounds with the target proteins.
一系列1-(取代苯甲酰基)-5-甲基吡咯并[1,2-]喹啉-3-羧酸乙酯以及1-(取代苯甲酰基)-5-甲基吡咯并[1,2-]喹啉-2,3-二羧酸二甲酯已被合成,并通过刃天青微板法(REMA)评估了它们对H37Rv(美国典型培养物保藏中心(ATCC)菌株25177)和耐多药(MDR)菌株的抗结核(TB)活性。还通过计算方法对这些化合物进行了分子靶点鉴定。所有测试化合物对H37Rv均表现出8-128μg/mL范围内的抗结核(TB)活性。测试化合物1-(4-氟苯甲酰基)-5-甲基吡咯并[1,2-]喹啉-2,3-二羧酸二甲酯分别在8和16μg/mL时,成为针对H37Rv和耐多药菌株最有前景的抗结核药物。对药代动力学性质的计算机模拟评估表明,大多数化合物总体上具有药物相似性。还进行了对接研究,以研究这些化合物与靶蛋白的结合亲和力以及相互作用。